cfChIPFrag-Seq: Integrated cfChIP-seq and cfDNA Fragmentomics Service
Limited plasma makes it difficult to compare circulating histone marks and native cfDNA fragmentation when the data layers come from different aliquots, batches, or pre-analytical histories.
cfChIPFrag-Seq prepares paired immunoprecipitated (IP) and Input libraries from the same qualified cell-free DNA or circulating-nucleosome specimen, connecting selected histone-mark enrichment with matched cfDNA fragmentomics.
Why researchers choose cfChIPFrag-Seq
Paired IP and Input libraries link histone-mark signal with native cfDNA fragment features from the same specimen.
Configurable histone-mark selection supports promoter-, enhancer-, transcription-, or repression-oriented research questions.
Fragment size, end motifs, breakpoint motifs, nucleosome footprints, and optional coverage-based analysis expand the information recovered from the Input library.
Circulating cell-free DNA is released as a mixture of naked and protein-associated fragments. A substantial fraction is protected by nucleosomes and can retain histone modifications from contributing cells. At the same time, fragment length, genomic position, and end sequence reflect nucleosome organization, nuclease activity, and pre-analytical handling.
cfChIPFrag-Seq combines two complementary views of this material:
IP library — histone-mark layer. An antibody enriches circulating nucleosomes carrying a selected histone modification. Sequencing reveals the genomic distribution of the enriched signal and supports promoter, enhancer, gene-body, or repressive-chromatin interpretation according to the selected mark.
Input library — fragmentomics layer. A matched, unenriched cfDNA library is prepared without antibody capture. Paired-end sequencing preserves fragment start, end, and length information as far as the extraction and library chemistry allow, enabling fragmentomics analysis and providing a matched background for IP interpretation.
The two arms are coordinated within one project, but they are not a single library. The starting specimen must contain enough material to allocate both arms, and each arm has its own library-quality and sequencing-quality checkpoints.
Histone modifications and fragmentation are biologically connected but answer different questions. The IP library asks where a selected chromatin mark is represented in circulating nucleosomes. The Input library asks how the broader cfDNA population is cut, protected, and distributed.
Add regulatory context to fragment patterns
Feature: Selected-mark enrichment is analyzed beside regional fragment-size, end, and nucleosome features.
Benefit: A descriptive fragmentation change can be placed in promoter, enhancer, transcribed, or repressed genomic context.
Research advantage: Teams can prioritize mechanistic hypotheses instead of treating every fragment shift as equivalent.
Use a specimen-matched background
Feature: The Input library originates from the same qualified specimen as the IP arm.
Benefit: Coverage, mappability, and sample-specific cfDNA composition can be reviewed against a natural matched reference.
Research advantage: Cross-arm interpretation does not depend on assuming that an unrelated control has the same cfDNA background.
Coordinate two data layers in one project
Feature: Sample allocation, paired libraries, sequencing, and bioinformatics are planned together.
Benefit: Technical decisions are documented before they create disconnected datasets.
Research advantage: Teams receive aligned histone-mark and fragmentomics outputs without managing separate workflows.
Input matching does not remove every source of bias. Antibody specificity, IP efficiency, GC composition, mappability, copy-number state, library complexity, and sequencing depth still require explicit quality control and appropriate normalization.
Service Fit
When to Choose cfChIPFrag-Seq
Approach
Best for
Not for / boundary
cfChIPFrag-Seq
Selected circulating histone marks and native cfDNA fragmentomics from the same specimen, with matched cross-arm interpretation
Not a single-library assay, a mutation-first panel, or a diagnostic test
cfChIP-seq
Focused profiling of one or more circulating histone modifications when a full native-fragmentomics layer is not required
Does not by itself deliver the complete unenriched fragmentomics feature set
Low-pass WGS fragmentomics
Cohort-scale fragment-size, end-motif, nucleosome-footprint, and coverage-based discovery without antibody enrichment
Does not directly isolate nucleosomes carrying a selected histone mark
Targeted mutation sequencing
Sensitive interrogation of predefined genomic variants
Does not provide genome-wide histone-mark or native-fragmentation context
cfChIPFrag-Seq is best suited to hypothesis-driven discovery and translational research in which the relationship between chromatin state and cfDNA fragmentation is itself part of the scientific question. For broader multi-analyte study design, see our liquid biopsy solutions.
Workflow
cfChIPFrag-Seq Project Workflow
The workflow separates scientific decisions from laboratory execution and places review gates before sequencing and integration.
Study design and mark selection — Define the biological question, cohort, comparison groups, confounders, sample matrix, desired histone mark, fragmentomics endpoints, and validation plan.
Plasma preparation or specimen review — Confirm collection tube, processing interval, storage history, freeze-thaw count, and specimen volume before extraction.
Cell-free DNA / circulating-nucleosome extraction — Recover low-abundance material while minimizing genomic DNA contamination and pre-analytical fragmentation.
Specimen allocation — Divide qualified material between the IP and Input arms according to yield, mark, and project design.
IP library preparation — Capture nucleosomes with the selected antibody, recover the marked DNA, construct the indexed library, and assess enrichment and library quality.
Input library preparation — Construct a matched unenriched paired-end library under conditions selected to preserve native fragment boundaries as far as practicable.
Coordinated sequencing — Sequence IP and Input libraries with project-specific read configuration and depth.
Integrated bioinformatics — Process each arm independently, apply arm-specific QC, then compare histone-mark signal with fragment-level and region-level features.
Decision gates are placed after specimen QC and library QC. Samples or libraries that do not meet agreed criteria are reviewed before sequencing or downstream integration.
Histone Marks
Configurable Histone-Mark Profiling
The histone mark should be selected from the biological question rather than from a fixed panel.
Candidate active and regulatory marks
H3K4me3 — promoter-associated signal that can support research into active or poised transcriptional programs.
H3K27ac — active promoter and enhancer context for regulatory-state and tissue-contribution hypotheses.
H3K36me3 — gene-body signal associated with transcriptional elongation.
Candidate repressive mark and feasibility controls
Final mark availability, antibody lot, expected enrichment profile, and feasibility are confirmed during project review.
A mark that performs well in conventional cellular ChIP-seq is not assumed automatically to perform identically with low-abundance circulating nucleosomes.
Typical IP-arm processing includes read QC, alignment, duplicate review, library-complexity assessment, enrichment and background metrics, signal-track generation, enriched-region or peak calling when appropriate, genomic annotation, chromosome-level summaries, motif analysis where scientifically justified, and comparison with selected reference epigenomic datasets.
Antibody identity and lot-specific evidence are recorded because specificity directly affects which fragments enter the IP library. This control reduces the risk that an apparent biological difference is driven by off-target capture or variable enrichment.
Fragmentomics
cfDNA Fragmentomics Analysis From the Input Library
The Input library is analyzed as an unenriched cfDNA population. Core modules can include:
Fragment length
Global, chromosome-level, and locus-level fragment size distribution and fragment size ratio. Exact bins are prespecified rather than treated as universal biological cutoffs.
Fragment ends
End-motif diversity and frequency, breakpoint motifs, preferred ends, and recurring cleavage coordinates.
Nucleosome footprints
Coverage and endpoint patterns around promoters, enhancers, open-chromatin regions, or other selected genomic annotations.
Coverage context
Broad copy-number patterns may be added when sequencing depth, tumor fraction, and data quality are suitable.
Regional matrices
Features aggregated over genes, regulatory regions, chromatin states, or project-specific intervals for statistical modeling.
Batch-aware QC
Insert-size, duplication, mapping, GC, and cross-sample metrics are reviewed before biological modeling.
Library preparation can alter end structure and representation. Fragmentomics outputs are interpreted together with laboratory and sequencing QC. Cross-cohort models require batch-aware study design and independent validation.
Deliverables
Integrated Bioinformatics and Deliverables
The two arms retain distinct measurement scales and are integrated only after independent processing and QC.
IP-arm outputs
FASTQ and aligned-read files
Library and enrichment QC summaries
Normalized signal tracks and enriched-region or peak tables, where appropriate
Fragment-size, fragment-ratio, end-motif, breakpoint-motif, and nucleosome-footprint matrices
Optional copy-number profiles and regional coverage summaries when technically supported
QC plots for library complexity, mapping, insert size, GC behavior, and cross-sample consistency
Integrated outputs
IP-to-Input enrichment and background comparisons
Histone-mark-linked fragmentation summaries across selected annotations
Cross-arm correlation matrices, heatmaps, browser tracks, and project-specific plots
Methods, parameter, and reference-version documentation
Input is a matched background, not an all-purpose correction factor. The final analysis plan states which comparisons are direct measurements, which are normalized estimates, and which are model-based interpretations.
Example cfChIPFrag-Seq Outputs
The planned dashboard illustrates the output families that can be coordinated in one report. Values remain illustrative until they are generated from project data.
Sample
Sample Requirements and Pre-analytical Controls
Item
Planning guidance
Preferred specimen
Human plasma; other cell-free biofluids require project-specific feasibility review
Recommended starting volume
At least 5 mL plasma for the combined IP/Input workflow; the final requirement depends on yield, selected mark, number of IP arms, and analysis scope
Collection
EDTA or a validated cfDNA stabilization tube; heparin is not recommended because downstream enzymatic reactions may be inhibited
Plasma separation
Process promptly under a standardized protocol, or follow the stabilization-tube instructions
Storage and shipment
Aliquot in nuclease-free cryovials, store frozen as agreed, ship on dry ice, and minimize freeze-thaw cycles
Residual cells and high-molecular-weight genomic DNA can distort both enrichment and fragment-size profiles. Cohorts should use consistent collection, separation, storage, and shipment procedures, with cases and controls distributed across processing batches.
Applications
Research Applications
Tissue- and cell-of-origin research
Compare promoter-, enhancer-, gene-body-, or repression-associated IP signals with regional fragmentation patterns to generate tissue-contribution hypotheses.
Regulatory-state studies
Investigate whether changes in circulating chromatin marks coincide with shifts in fragment size, ends, or nucleosome footprints across selected pathways and genomic regions.
Biomarker discovery
Build candidate feature sets that combine histone-mark signals with fragmentomics matrices, then evaluate them with prespecified training, validation, and confounder-control strategies.
Longitudinal research
Explore whether epigenomic and fragmentomic features change together across paired research time points with batch-balanced processing.
Multi-omics programs
Combine cfChIPFrag-Seq outputs with mutation, methylation, cfRNA, or tissue data when each layer answers a prespecified question.
For study programs moving from broad signals to candidate prioritization and validation planning, our biomarker discovery solutions can extend the analysis framework.
Advantages
Why Work With CD Genomics?
One coordinated design
Sample allocation, mark choice, IP, Input, sequencing, and cross-arm analysis are planned before processing, reducing avoidable inconsistencies.
Arm-specific quality control
Enrichment metrics are not substituted for fragmentomics QC, and fragmentomics metrics are not used as proof of antibody specificity.
Configurable analysis
Mark, genomic annotations, feature modules, comparisons, and deliverables are selected for the research question.
Transparent boundaries
Fixed performance, diagnostic accuracy, and universal sample thresholds are not promised before project feasibility review.
Case Study
Case Study: Fragmentation Features Vary With Tumor Cell and Anatomical Context
Source: Fu R, Su HA, Zhao Y, Tian Y, Chen H, Lu D. Dissecting cell-free DNA fragmentation variation in tumors using cell line-derived xenograft mouse. PLOS ONE. 2025;20(7):e0327483. https://doi.org/10.1371/journal.pone.0327483
Tumor-bearing plasma contains both tumor-derived and non-tumor cfDNA, making it difficult to determine which component contributes a fragmentation pattern. The study used cell line-derived xenograft mouse models to separate human tumor-derived fragments from mouse cfDNA computationally.
Human MHCC-97H liver carcinoma and A549 lung carcinoma cells were implanted in different anatomical sites in mice. The investigators analyzed cfDNA fragment-size distribution, breakpoint motifs, and end motifs, then compared features by tumor cell line and implantation site.
Both xenograft-plasma cfDNA and tumor-derived cfDNA showed enrichment of shorter fragments relative to normal plasma, with a stronger short-fragment shift in the tumor-derived component. Fragmentation features in the whole xenograft-plasma cfDNA differentiated models by tumor cell line, whereas tumor-derived fragment features showed stronger separation by anatomical site.
The study shows that fragmentation features can be influenced by both the originating tumor cells and the local biological environment. For cfChIPFrag-Seq planning, this supports cohort matching, pre-analytical standardization, and regional interpretation instead of assuming that one fragment signature is universal. The paper evaluates the fragmentomics layer; it does not validate the IP arm or the performance of the CD Genomics service.
FAQ
Frequently Asked Questions
Q1. Is cfChIPFrag-Seq a single library?
No. Qualified material from the same specimen is allocated to two coordinated libraries: an antibody-enriched IP library and an unenriched Input library. This pairing supports matched interpretation while preserving the different measurement roles of each arm.
Q2. Which histone marks can be profiled?
Candidate marks include H3K4me3, H3K27ac, H3K36me3, and H3K27me3. Final availability and suitability depend on the biological question, antibody evidence, specimen type, input amount, and expected enrichment pattern.
Q3. Does the Input library perfectly correct the IP signal?
No. It provides a matched background for coverage and enrichment assessment, but antibody efficiency, GC and mappability effects, copy-number state, library complexity, and sequencing depth still require explicit modeling and QC.
Q4. Can one Input library support both fragmentomics and copy-number analysis?
Potentially. Paired-end Input data can support fragment-size and end-based analyses, while broad copy-number profiling may be added when depth, tumor fraction, and data quality are adequate. Feasibility is confirmed in the project design.
Q5. Why is at least 5 mL plasma recommended?
The combined workflow divides extracted material between IP and Input arms, and additional IP marks require further allocation. Five milliliters is a planning recommendation for this combined service, not a universal acceptance threshold; yield and project scope determine the final requirement.
Q6. Can cfChIPFrag-Seq data be used to train a classifier?
Yes, as a research analysis. Classifier design should prespecify endpoints, confounders, training and validation splits, batch handling, and an independent validation cohort. Model outputs are not equivalent to clinical validation.
